XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:      
Net loss $ (679,171) $ (272,072) $ (176,782)
Adjustments to reconcile net loss to net cash used in operating activities:      
Goodwill Impairment 436,479    
Depreciation and amortization expense 31,512 26,167 16,089
Provisions for credit losses 1,057 806 714
Amortization of deferred contract acquisition costs 2,261 1,684 1,971
Amortization of deferred contract fulfillment costs 432 620 737
Noncash compensation costs incurred by selling shareholders   11,139 2,753
Accretion of discounts on debt securities (10,010)    
Interest on debt securities 10,010    
Stock-based compensation expense 72,246 67,675 43,809
Loss on equity method investment 2,590 2,278 3,132
Deferred income taxes (242) (2,524) (6,245)
Changes in operating assets and liabilities, net of acquisition:      
Accounts receivable 3,248 (8,140) (512)
Inventories 2,085 (1,207) 1,598
Deferred contract acquisition costs (4,499) (2,771) (2,235)
Prepaid expenses and other current assets 4,694 (161) (5,775)
Other assets (76) (235) 117
Accounts payable (2,361) (4,780) 5,546
Accrued expenses and other current liabilities (15,139) 8,962 (380)
Other long-term liabilities   (25) (16,705)
Deferred revenue (3,459) (19,739) (9,369)
Net cash used in operating activities (148,343) (192,323) (141,537)
Cash flows from investing activities:      
Purchases of property and equipment (192) (292) (559)
Capitalized software development costs (15,056) (10,155)  
Investment in less than majority owned joint venture (3,920) (1,960) (2,548)
Purchases of investments (389,990) (499,223)  
Proceeds from sales and maturities of investments 389,990 500,000 100,000
Acquisitions of business, net of cash acquired     (156,526)
Net cash used in investing activities (19,168) (11,630) (59,633)
Cash flows from financing activities:      
Proceeds from exercise of common stock options 569 5,740 20,806
Proceeds from employee stock purchase plan 2,164 2,503 1,599
Payments for the purchase of treasury stock (586) (360) (15,038)
Proceeds from Section 16(b) disgorgement   295  
Payment of contingent consideration   (11,790)  
Payment of deferred offering costs     (1,613)
Net cash (used in) provided by financing activities 2,147 (3,612) 5,754
Effect of exchange rates changes on cash, cash equivalents, and restricted cash (1,144) (305) (84)
Net (decrease) increase in cash, cash equivalents, and restricted cash (166,508) (207,870) (195,500)
Cash, cash equivalents, and restricted cash at beginning of period 539,341 747,211 942,711
Cash, cash equivalents, and restricted cash at end of period 372,833 539,341 747,211
Cash, cash equivalents, and restricted cash at end of period:      
Cash and cash equivalents 372,038 538,546 746,416
Restricted cash 795 795 795
Total cash, cash equivalents, and restricted cash at end of period 372,833 539,341 747,211
Supplemental disclosure of cash flow information:      
Cash paid for income taxes $ 5,003 1,723 1,587
Supplemental disclosure of non-cash investing and financing activities:      
Issuance of common stock in acquisitions     144,107
Issuance of common stock in settlement of earnout   $ 17,243  
Receivable related to exercise of common stock options     $ 74